Search
Vaccines Treatment Options
A collection of 947 research studies where Vaccines is the interventional treatment. These studies are located in the United States. Vaccines is used for conditions such as Influenza, COVID-19 and Hepatitis B.
157 - 168 of 947
Match to Clinical Trials
Access to cutting-edge treatments
Latest clinical trials
Find trials in your area
Search by Name
Filter by Condition
Filter by Age
Filter by Type
Gender
Type of Study
Clinical Trial Phase
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Offer
Lose Weight with GLP-1 Medications
Recruiting
Policy Lab has partnered with CareGLP to offer trusted access to GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
Conditions:
Overweight
Overweight and Obesity
Obesity
Weight Loss
Morbid Obesity
Study of an Investigational Pentavalent Meningococcal ABCYW Vaccine in Adults and Adolescents
Active Not Recruiting
The purpose of VAN00010 study is to assess the safety and immunogenicity of the investigational pentavalent meningococcal ABCYW vaccine in adults and adolescents.
The study duration will be up to 12 months for all participants.
Gender:
ALL
Ages:
Between 10 years and 25 years
Trial Updated:
01/10/2025
Locations: Accel Research Site - Birmingham Clinical Research Unit- Site Number : 8400080, Birmingham, Alabama +46 locations
Conditions: Healthy Volunteers, Meningococcal Immunisation
Neoantigen-based Personalized DNA Vaccine in Patients With Newly Diagnosed, Unmethylated Glioblastoma
Active Not Recruiting
This is a single institution, open-label, single arm, study assessing the safety, feasibility, and immunogenicity of a personalized neoantigen-based vaccine in subjects with newly diagnosed, unmethylated glioblastoma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/08/2025
Locations: Washington University School of Medicine, Saint Louis, Missouri
Conditions: Glioblastoma
Personalized Peptide Vaccine in Treating Patients With Advanced Pancreatic Cancer or Colorectal Cancer
Recruiting
This phase I trial studies the side effects and best way to give personalized peptide vaccine in patients with pancreatic or colorectal cancer that has spread to other places in the body and usually cannot be cured or controlled with treatment (advanced). Personalized peptide vaccine is a vaccine developed from patient's own tumor cells and blood in order to use as a biological therapy. Biological therapies, such as personalized peptide vaccine may attack tumor cells and stop them from growing o... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/08/2025
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Stage IV Colorectal Cancer AJCC v7, Stage IV Pancreatic Cancer AJCC v6 and v7, Stage IVA Colorectal Cancer AJCC v7, Stage IVB Colorectal Cancer AJCC v7, Metastatic Colorectal Adenocarcinoma, Metastatic Pancreatic Ductal Adenocarcinoma
Systems Biological Assessment of Statin Effect on Vaccine Responses
Completed
This study is being done to answer the question: Does the use of statin lipid-lowering medication change the effect of influenza vaccine? The research team will use the knowledge gained from answering this question to understand how this medication affects long-lasting immune responses to vaccines. The researchers will study the immune response to the influenza vaccine in the blood (where antibodies are). The team will also look at how statin therapy affects the bacteria that live in the gut by... Read More
Gender:
ALL
Ages:
Between 18 years and 50 years
Trial Updated:
01/06/2025
Locations: Hope Clinic, Atlanta, Georgia
Conditions: Vaccine Response
A Synthetic MVA-based SARS-CoV-2 Vaccine, GEO-CM04S1, for the Prevention of COVID-19 Infection
Active Not Recruiting
This phase I trial evaluates the side effects and best dose of GEO-CM04S1 (previously designated as COH04S1), a synthetic modified vaccinia Ankara (MVA)-based SARS-CoV-2 vaccine, for the prevention of COVID-19 infection. COVID-19 infection is caused by the SARS-CoV-2 virus. SARS-CoV-2 has demonstrated the capability to spread rapidly, leading to significant impacts on healthcare systems and causing societal disruption. GEO-CM04S1 was created by placing small pieces of SARS-CoV-2 DNA (the chemica... Read More
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
01/02/2025
Locations: EmVenio Research, Claremont, California +2 locations
Conditions: COVID-19 Infection
Anti-pneumococcal Vaccine Strategy in Patients with Chronic Lymphocytic Leukemia
Recruiting
This phase II trial compares the effect of initial vaccination (PCV20 followed by PSV23) with yearly vaccinations of PSV23 to the standard 5 year vaccination in patients with chronic lymphocytic leukemia. At present chronic lymphocytic leukemia patients are poorly protected by anti-pneumococcal vaccination. Current vaccination schedule for chronic lymphocytic leukemia patients is based on general recommendations in immunocompromised patients (initial vaccination with PCV13 followed by one dose o... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/27/2024
Locations: Ohio State University Comprehensive Cancer Center, Columbus, Ohio
Conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
A Study to Learn About the Safety and Immune Response of a New Pneumococcal Vaccine in Adults
Active Not Recruiting
The purpose of this study is to learn about the safety and immune effects of a pneumococcal vaccine in adults. This vaccine can possibly provide protection against further pneumococcal disease.
This study will happen in 3 stages: Stage 1 is seeking participants who are between 18 years to 49 years of age. The participants will receive 1 of 2 pneumococcal vaccine candidates (different formulations) or 20vPnC (Prevnar 20) as a single shot given into the upper arm muscle.
Stage 2 will begin after... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/23/2024
Locations: Alliance for Multispecialty Research, LLC, Coral Gables, Florida +16 locations
Conditions: Pneumococcal Disease
Pilot Study With CY, Pembrolizumab, GVAX, and IMC-CS4 (LY3022855) in Patients With Borderline Resectable Adenocarcinoma of the Pancreas
Completed
The purpose of this study is to evaluate whether combining cyclophosphamide (CY), pembrolizumab, GVAX and IMC-CS4 is effective and safe in patients with borderline resectable pancreatic cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/23/2024
Locations: Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland
Conditions: Pancreatic Cancer
A Study of mRNA-based Influenza and SARS-CoV-2 (COVID-19) Multi-component Vaccines in Healthy Adults
Completed
The study is divided into 2 parts: Part 1 and Part 2. The purpose of Part 1 of this study is to generate sufficient safety, reactogenicity, and immunogenicity data to enable selection of an mRNA-1083 vaccine composition and dose level to evaluate in a subsequent Phase 3 clinical trial in adults.
The purpose of Part 2 of this study is to generate safety and immunogenicity data for additional mRNA-1083 compositions and dose levels in young adults ≥18 years and \<50 years of age.
Gender:
ALL
Ages:
Between 18 years and 79 years
Trial Updated:
12/21/2024
Locations: Chandler Clinical Trials, Chandler, Arizona +68 locations
Conditions: SARS-CoV-2, Influenza
A Study of mRNA-1010 Seasonal Influenza Vaccine in Adults 50 Years Old and Older
Completed
The purpose of this study is to evaluate the safety and efficacy of mRNA-1010 in preventing seasonal influenza in adults 50 years and older.
Gender:
ALL
Ages:
50 years and above
Trial Updated:
12/20/2024
Locations: North Alabama Research Center, LLC, Athens, Alabama +232 locations
Conditions: Seasonal Influenza
An Exploratory Open-Label Clinical Trial Evaluating the Immunogenicity of the 9-valent 2-dose HPV Vaccination Regimen
Active Not Recruiting
The goal of this study is to explore and evaluate whether a 2-dose schedule of Gardasil 9 among young and mid-adult women 16-45 years of age is generally safe and immunogenic, with an antibody response that is not inferior to that observed of a 3-dose schedule of Gardasil 9 among women aged 16-26 years old. The investigators thought that having a 2-dose vaccination regimen for individuals 16 to 45 would provide a more robust dataset than those of 27 to 45 years old.
Gender:
FEMALE
Ages:
Between 16 years and 45 years
Trial Updated:
12/20/2024
Locations: Boston Medical Center, Boston, Massachusetts
Conditions: HPV Infection
A Trial to Describe the Safety and Immunogenicity of MenABCWY When Administered on 2 Schedules
Completed
This study is designed to describe the short-term immunogenicity and safety of 2 doses of Neisseria meningitidis group A, B, C, W, and Y vaccine (MenABCWY) separated by either 12 or 36 months during adolescence, and immunopersistence up to 24 months after completing 2 doses separated by a 12-month interval.
Gender:
ALL
Ages:
Between 11 years and 14 years
Trial Updated:
12/17/2024
Locations: Alliance for Multispecialty Research, LLC, Mobile, Alabama +19 locations
Conditions: Meningococcal Vaccine
157 - 168 of 947